Clinical Trial

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

A rare disease drug's EU approval is revoked over 'misleading' data, impacting patients and signaling a new era of strict regulatory scrutiny for pharma giants.

An independent safety board just gave Medera's novel gene therapy for a stubborn form of heart failure a major endorsement, de-risking its path to the FDA.

NeuroSense's PrimeC shows intriguing biomarker activity against Alzheimer's, targeting multiple disease pathways. Is this the shift away from single-target drugs?

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

Promising 3-year survival data for a novel immunotherapy combo offers new hope for patients with MSS colorectal cancer, a notoriously difficult disease.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.

Insmed and EMBARC's 3,000-patient study of brensocatib aims to do more than treat a chronic lung disease—it aims to fundamentally alter its course.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.